Tourmaline Bio, Inc. (NASDAQ: TRML) has announced several key clinical and strategic updates at its investor day event. The phase 2 tranquility trial, which evaluates the dosing of pacibekitug in patients with elevated high-sensitivity c-reactive protein and chronic kidney disease, has surpassed its enrollment target with 143 total patients enrolled, exceeding the originally anticipated 120 patients. The company expects to report topline data from this trial in the second quarter of 2025.
Moreover, Tourmaline has expanded its cardiovascular scientific advisory board (CV SAB) with the appointment of Deepak L. Bhatt, MD, MPH, MBA, FAC, FAHA, FESC, MSCAI as the chair and Dipender Gill, MD, PhD, CEO of Sequoia Genetics, as a new member. The company has also nominated abdominal aortic aneurysm (AAA) as an additional indication within its cardiovascular inflammation disease focus for pacibekitug, with plans to provide additional details on a planned phase 2 proof-of-concept trial in AAA after the topline results from the phase 2 tranquility trial are reported in Q2 2025.
In terms of the thyroid eye disease (TED) development program, Tourmaline has indicated that the initiation of a phase 3 trial will be dependent upon the results from the ongoing phase 2b spirited trial, with topline data from the latter expected in the second half of 2025.
These developments reflect Tourmaline's commitment to advancing its pipeline and strategic priorities, with a focus on addressing inflammation-driven cardiovascular diseases and immune and inflammatory diseases.
The company's investor day took place on December 10, 2024, and a replay of the webcast will be available on Tourmaline's website following the event. As a result of these announcements, the company's shares have moved -2.2% on the market, and are now trading at a price of $24.8. For more information, read the company's full 8-K submission here.
